Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 65.

Moch, H; Blank, P R; Dietel, M; Elmberger, G; Kerr, K M; Palacios, J; Penault-Llorca, F; Rossi, G; Szucs, T D (2012). Personalized cancer medicine and the future of pathology. Virchows Archiv, 460(1):3-8.

Schwenkglenks, M; Brazier, J E; Szucs, T D; Fox, K A A (2011). Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. Value in Health, 14(1):24-33.

Matter-Walstra, K; Schwenkglenks, M; Szucs, T D; Pestalozzi, B (2011). How to get involved in a health economic analysis: an introduction for clinical researchers. Schweizer Krebs-Bulletin = Bulletin Suisse du Cancer, 31(2):144-146.

Blank, P R; Moch, H; Szucs, T D; Schwenkglenks, M (2011). KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clinical Cancer Research, 17(19):6338-6346.

Szucs, T D; Blank, P R; Schwenkglenks, M; Aapro, M (2011). Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia. Oncology, 81(1):45-49.

Volz Wenger, A; Szucs, T D (2011). Predictors of family communication of one's organ donation intention in Switzerland. International Journal of Public Health, 56(2):217-223.

Schwenkglenks, M; Pettengell, R; Jackisch, C; Paridaens, R; Constenla, M; Bosly, A; Szucs, T D; Leonard, R (2011). Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. Supportive Care in Cancer, 19(4):483-490.

Blank, P R; Dedes, K J; Szucs, T D (2010). Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review. PharmacoEconomics, 28(8):629-647.

Szucs, T D; Waeber, B; Tomonaga, Y (2010). Cost-effectiveness of antihypertensive treatment in patients 80 years of age or older in Switzerland: an analysis of the HYVET study from a Swiss perspective. Journal of Human Hypertension, 24(2):117-123.

Blank, P R; Blank, A A; Szucs, T D (2010). Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema--a long-term analysis from a Swiss perspective. BMC Dermatology, 10:4.

Schwenkglenks, M; Pettengell, R; Szucs, T D; Culakova, E; Lyman, G H (2010). Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery. Journal of Hematology and Oncology, 3:27.

Blank, P R; Schwenkglenks, M; Moch, H; Szucs, T D (2010). Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. Breast Cancer Research and Treatment, 124(2):497-507.

Matter-Walstra, K W; Dedes, K J; Schwenkglenks, M; Brauchli, P; Szucs, T D; Pestalozzi, B C (2010). Trastuzumab beyond progression: a cost-utility analysis. Annals of Oncology, 21(11):2161-2168.

Dedes, K J; Matter-Walstra, K; Schwenkglenks, M; Pestalozzi, B C; Fink, D; Brauchli, P; Szucs, T D (2009). Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. European Journal of Cancer, 45(8):1397-1406.

Szucs, T D; Thalmann, C; Michetti, P; Beglinger, C (2009). Cost Analysis of Long-Term Treatment of Patients with Symptomatic Gastroesophageal Reflux Disease (GERD) with Esomeprazole On-Demand Treatment or Esomeprazole Continuous Treatment: An Open, Randomized, Multicenter Study in Switzerland. Value in Health, 12(2):273-281.

Blank, P R; Schwenkglenks, M; Szucs, T D (2009). Disparities in Influenza Vaccination Coverage Rates by Target Group in Five European Countries: Trends Over Seven Consecutive Seasons. Infection, 37(5):390-400.

Blank, P R; Szucs, T D (2009). Increasing influenza vaccination coverage in recommended population groups in Europe. Expert Review of Vaccines, 8(4):425-433.

Endrich, M M; Blank, P R; Szucs, T D (2009). Influenza vaccination uptake and socioeconomic determinants in 11 European countries. Vaccine, 27(30):4018-4024.

Blank, P R; Schwenkglenks, M; Szucs, T D (2009). Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. Journal of Infection, 58(6):441-453.

Pettengell, R; Bosly, A; Szucs, T D; Jackisch, C; Leonard, R; Paridaens, R; Constenla, M; Schwenkglenks, M (2008). Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. British Journal of Haematology, 144(5):677-685.

Blank, P R; Freiburghaus, A U; Ruf, B R; Schwenkglenks, M M; Szucs, T D (2008). Trends in Influenza Vaccination Coverage Rates in Germany over Six Seasons from 2001/02 to 2006/07. Medizinische Klinik, 103(11):761-768.

Jennings, L C; Monto, A S; Chan, P K S; Szucs, T D; Nicholson, K G (2008). Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infectious Diseases, 8(10):650-658.

Szucs, T D; Largeron, N; Dedes, K J; Rafia, R; Bénard, S (2008). Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Current Medical Research and Opinion, 24(5):1473-1483.

Szucs, T D (2008). Can we afford the war on cancer? Onkologie, 31(3):81.

Szucs, T D; Dedes, K J (2008). Balancing costs and benefits in cancer therapy and prevention. Annals of Oncology, 19(Suppl.):vii313-vii319.

Wang, M; Szucs, T D; Steffen, R (2008). Economic aspects of travelers’ diarrhea. Journal of Travel Medicine, 15(2):110-118.

Blank, P R; Freiburghaus, A U; Schwenkglenks, M; Szucs, T D; Kunze, U (2008). Influenza vaccination coverage rates in Austria in 2006/07 - a representative cross-sectional telephone survey. Wiener Medizinische Wochenschrift, 158(19-20):583-588.

Blank, P R; Schwenkglenks, M; Szucs, T D (2008). Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons. BMC Public Health, 8:272.

Bramkamp, M; Szucs, T D (2008). Kosten-Nutzen-Effektivität von Clopidogrel bei akutem Koronarsyndrom: Langzeitbehandlung, sekundäre Prophylaxe, Koronarintervention. Herz, 33(1):60-70.

Pettengell, R; Schwenkglenks, M; Leonard, R; Bosly, A; Paridaens, R; Constenla, M; Szucs, T D; Jackisch, C (2008). Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Supportive Care in Cancer, 16(11):1299-1309.

Blank, P R; Freiburghaus, A U; Schwenkglenks, M; Szucs, T D (2008). Trends in influenza vaccination coverage rates in the United Kingdom over six seasons from 2001-2 to 2006-7. Euro Surveillance, 13(43):1-7.

Lina, B; Holm, M V; Szucs, T D (2008). Évolution du taux de couverture vaccinale contre la grippe en France : de 2001 à 2006. Médecine et Maladies Infectieuses, 38(3):125-132.

Müller, D; Szucs, T D (2007). Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional analysis of the seasons 02/03, 03/04 and 04/05. Infection, 35(5):308-319.

Holm, M V; Szucs, T D; Fara, G M (2007). Developments in influenza vaccination coverage in Italy over five seasons (2001-2006). Annali di Igiene Medicina Preventiva e di Comunita, 19(5):405-415.

Dedes, K J; Szucs, T D; Imesch, P; Fedier, A; Fehr, M K; Fink, D (2007). Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Annals of Oncology, 18(9):1493-1499.

Holm, M V; Blank, P R; Szucs, T D (2007). Developments in influenza vaccination coverage in England, Scotland and Wales covering five consecutive seasons from 2001 to 2006. Vaccine, 25(46):7931-7938.

Holm, M V; Blank, P R; Szucs, T D (2007). Influenza vaccination coverage rates in Europe – covering five consecutive seasons (2001–2006) in five countries. Influenza and Other Respiratory Viruses, 1(5-6):215-221.

Holm, M V; Blank, P R; Szucs, T D (2007). Trends in influenza vaccination coverage rates in Germany over five seasons from 2001 to 2006. BMC Infectious Diseases, 7:144.

Szucs, T D; Holm, M V; Schwenkglenks, M; Zhang, Z; Weintraub, W S; Burnier, M; Erne, P (2006). Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction - an analysis of the EPHESUS study from a Swiss perspective. Cardiovascular Drugs and Therapy, 20(3):193-204.

Schwenkglenks, M; Jackisch, C; Constenla, M; Kerger, J N; Paridaens, R; Auerbach, L; Bosly, A; Pettengell, R; Szucs, T D; Leonard, R (2006). Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Supportive Care in Cancer, 14(9):901-909.

Müller, D; Saliou, P; Szucs, T D (2006). Coverage rates of influenza vaccination in France: a population-based cross-sectional analysis of seasons 2001-2002 and 2002-2003. Médecine et Maladies Infectieuses, 36(1):36-41.

Schwenkglenks, M; Preiswerk, G; Lehner, R; Weber, F; Szucs, T D (2006). Economic efficiency of gate-keeping compared with fee for service plans: a Swiss example. Journal of Epidemiology & Community Health, 60(1):24-30.

Szucs, T D (2006). Healing unhealthy Hungarian hearts--at what cost?--With what benefit? Cardiovascular Drugs and Therapy, 20(4):239-43.

Müller, D; Nguyen-Van-Tam, J S; Szucs, T D (2006). Influenza vaccination coverage rates in the UK: a comparison of two monitoring methods during the 2002-2003 and 2003-2004 seasons. Public health, 120(11):1074-1080.

Szucs, T D; Wahle, K; Müller, D (2006). Influenza vaccination in Germany. A population-based cross-sectional analysis of three seasons between 2002 and 2005. Medizinische Klinik, 101(7):537-545.

Szucs, T D; Bramkamp, M (2006). Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review. Journal of Thrombosis and Haemostasis, 4(6):1180-1185.

Smektala, R; Ohmann, C; Paech, S; Neuhaus, E; Rieger, M; Schwabe, W; Debold, P; Deimling, A; Jonas, M; Hupe, K; Bücker-Nott, H J; Giani, G; Szucs, T D; Pientka, L (2005). Zur Prognose der Schenkelhalsfraktur. Der Unfallchirurg, 108(11):927-937.

Szucs, T D; Müller, D (2005). Influenza vaccination coverage rates in five European countries-a population-based cross-sectional analysis of two consecutive influenza seasons. Vaccine, 23(43):5055-5063.

Szucs, T D (2005). Medizinische Ökonomie in der Onkologie. Der Onkologe, 11(2):139-151.

Schwenkglenks, M; Lippuner, K; Häuselmann, H J; Szucs, T D (2005). A model of osteoporosis impact in Switzerland 2000–2020. Osteoporosis International, 16(6):659-671.

Müller, D; Juanes, J R; Szucs, T D (2005). Cobertura de la vacunación frente a la gripe en España : Análisis de las temporadas 2002-2003 y 2003-2004. Vacunas, 6(4):116-122.

Szucs, T D; Schwenkglenks, M; Lüscher, T F; Eberli, F (2005). Die Wirtschaftlichkeit beschichteter Stents in der interventionellen Kardiologie - eine gesamtschweizerische Analyse. Kardiovaskuläre Medizin, 8:41-52.

Szucs, T D; Käser, A; Riesen, W F (2005). Economic impact of hyperhomocysteinemia in Switzerland. Cardiovascular Drugs and Therapy, 19(5):365-369.

Szucs, T D (2005). Health economic research on vaccinations and immunisation practices--an introductory primer. Vaccine, 23(17-18):2095-2103.

Szucs, T D (2005). Health economics in the genomic age. Recent Results in Cancer Research, 166:299-313.

Müller, D; Wutzler, P; Szucs, T D (2005). Influenza Vaccination Coverage Rates in Germany. Medizinische Klinik, 100(1):6-13.

Szucs, T D (2005). Meningococcal vaccination: cui bono? PharmacoEconomics, 23(4):315-316.

Dedes, K J; Bramkamp, M; Szucs, T D (2005). Paclitaxel: cost–effectiveness in ovarian cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 5(3):235-243.

Bramkamp, M; Dedes, K J; Szucs, T D (2005). Pharmacotherapy of acute coronary syndromes: medical economics with an emphasis on clopidogrel. Cardiovascular Drugs and Therapy, 19(4):291-299.

Coudeville, L; Brunot, A; Szucs, T D; Dervaux, B (2005). The economic value of childhood varicella vaccination in France and Germany. Value in Health, 8(3):209-222.

Schmitt-Koopmann, I; Schwenkglenks, Matthias; Spinas, G A; Szucs, T D (2004). Direct medical costs of type 2 diabetes and its complications in Switzerland. European Journal of Public Health, 14(1):3-9.

Beeler, I; Lorenz, S; Szucs, T D (2003). Provision and remuneration of psychotherapeutic services in Switzerland. Sozial- und Präventivmedizin, 48(2):88-97.

Die Kosten der körperlichen Inaktivität in der Schweiz. Edited by: Smala, A; Beeler, I; Szucs, T D (2001). Zürich: Abteilung für medizinische Ökonomie des Instituts für Sozial- und Präventivmedizin und des Universitätsspitals.

Martin, B W; Beeler, I; Szucs, T D; Smala, A; Brügger, O; Casparis, C; Allenbach, R; Raeber, P A; Marti, B (2001). Volkswirtschaftlicher Nutzen der Gesundheitseffekte der körperlichen Aktivität: erste Schätzungen für die Schweiz. Schweizerische Zeitschrift für Sportmedizin und Sporttraumatologie, 49(2):84-86.

Szucs, T D; Meyer, B J; Kiowski, W (1999). Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting; an analysis based on the PRISM PLUS trial. European Heart Journal, 20(17):1253-1260.

This list was generated on Wed Jun 19 20:46:43 2019 CEST.